Vogenx

Biotech · Pharmaceuticals · Rare Disease

IPO

Vogenx raises $81M in Nasdaq IPO to fund drug for untreated metabolic disease

The pricing tests how far Wall Street's reopened IPO window will stretch for small, thinly capitalized biotechs.

• Vogenx (Nasdaq: VOGX) closed its IPO on August 13, 2026, selling 6.25 million shares at $13 apiece for $81.3 million in gross proceeds, with JonesTrading as sole book-running manager.
• Vogenx is a clinical-stage biopharmaceutical company developing drugs for metabolic disorders with no FDA-approved treatments, including post-bariatric hypoglycemia and gastroparesis.
• Its lead candidate, mizagliflozin, is an oral SGLT1 inhibitor licensed from Japan's Kissei Pharmaceutical in 2021 for about $27 million in milestones plus royalties, now in a Phase IIb trial for post-bariatric hypoglycemia.
• Before the IPO, Vogenx had raised only about $11.5 million total since inception, through a 2021-22 Series A convertible preferred round and a December 2025 convertible note.
• The offering priced at $13, the top of its range, and VOGX began trading on the Nasdaq Capital Market on August 12, 2026.
• The successful pricing shows even thinly capitalized biotechs with early rare-disease data can still access public markets, a sign the 2026 IPO window has widened beyond well-funded names.